PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18971559-7	2008	Two-fold increases in ACAT1 protein expression and ACAT activity with Ang II treatment were completely inhibited by AT(1) receptor antagonists (candesartan, [Sar(1),Ile(8)]-Ang II), but not by an AT(2) receptor antagonist (PD123319).	candesartan	144-155	angiogenin	Homo sapiens	70-73	
21915376-4	2011	Prior to transfection, cells were treated with candesartan to block extracellular Ang II-induced responses via cell membrane AT1 receptors.	candesartan	47-58	angiogenin	Homo sapiens	82-85	
11788444-9	2002	The effects of luminal ANG II were furosemide sensitive and abolished by the AT(1) receptor blocker candesartan.	candesartan	100-111	angiogenin	Homo sapiens	23-26	
12915681-6	2003	Candesartan dramatically increased Ang II [177.9 pg/ml (113.3, 242.6)], compared with baseline [34.8 pg/ml (29.3, 40.4), P = 0.002] and furosemide alone [40.6 pg/ml (29.7, 51.5), P = 0.003].	candesartan	0-11	angiogenin	Homo sapiens	35-38	
11399656-5	2001	ANG II-mediated GFAT promoter activation was inhibited by the ANG II type I receptor antagonist candesartan (10(-8) M) but was unaffected by the ANG II type II receptor antagonist PD-123319 (10(-8) M).	candesartan	96-107	angiogenin	Homo sapiens	0-3	
11399656-5	2001	ANG II-mediated GFAT promoter activation was inhibited by the ANG II type I receptor antagonist candesartan (10(-8) M) but was unaffected by the ANG II type II receptor antagonist PD-123319 (10(-8) M).	candesartan	96-107	angiogenin	Homo sapiens	62-65	
11399656-5	2001	ANG II-mediated GFAT promoter activation was inhibited by the ANG II type I receptor antagonist candesartan (10(-8) M) but was unaffected by the ANG II type II receptor antagonist PD-123319 (10(-8) M).	candesartan	96-107	angiogenin	Homo sapiens	62-65	
11881058-7	2001	This remarkable response to candesartan in subjects on a high-salt diet,when compared with the response to captopril,suggests that non-ACE-dependent Ang II generation was influenced less than the classical renal pathway with an increase in salt intake, so that the percentage of Ang II generated via the non-ACE pathway rose to the 60-70% range.	candesartan	28-39	angiogenin	Homo sapiens	149-152	
10069643-8	1999	When hypertensive patients were treated with an AT1-R antagonist candesartan for 7 days, Ang II and Ang IV levels were increased 5.5- and 4.1-fold relative to the control levels, respectively.	candesartan	65-76	angiogenin	Homo sapiens	89-92